The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?

Samed Verep, Selcuk Erdem, Yasemin Ozluk, Isin Kilicaslan, Oner Sanli, Faruk Ozcan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Active surveillance (AS) is one of the treatment alternatives in low-risk prostate cancer (PCa). The pathological upgrading after radical prostatectomy (RP) were investigated in patients who were eligible for AS in the present study. Methods: Between August 2006 and July 2017, 627 patients underwent RP in our institution. One hundred and thirty-six patients who were eligible for AS at the time of RP were included in this study. The previously defined AS criteria Gleason 3 + 3=6 adenocarcinoma at maximum two biopsy cores, prostate-specific antigen (PSA) < 10 ng/mL and clinical T stage ≤ 2a were used in the study. The demographics, clinical, and histopathological outcomes were retrospectively compared between two groups, which were divided in accordance with the upgrading status at final pathology as Group 1 (n = 67, upgrading) and Group 2 (n = 69, nonupgrading). Results: Gleason upgrading (GU) was found in 67 (49.3%) patients, and 17 patients (12.5%) were upstaged to pT3a. The upgrading to Gleason 3 + 4 was reported in 38.7% of patients, however, 7.4%, and 3.7% of the patients were upgraded to Gleason 4 + 3, and Gleason 4 + 4, respectively. The 10.3% of the patients had extraprostatic involvement, and the rate (19.4% vs 1.4%, P =.002) was significantly higher in Group 1. PSA density (P =.001), tumor size (P <.001), tumor percentage (P <.001), apical involvement (P =.013), and perineural invasion (P <.001) in RP specimen were higher in Group 1. Multivariate analysis showed that perineural invasion (OR = 4.26; 95%CI: 1.76-10.33; P =.001) and pathologic T stage (OR = 5.45; 95%CI: 1.08-27.4; P =.04) were independently associated with GU. Conclusions: Since 12.5% of the patients upstaged to pT3a disease, and there is a possible risk of Gleason 4 pattern, upgrading of the tumor should carefully be kept in mind before offering AS to low-risk patients with PCa.

Original languageEnglish (US)
Pages (from-to)1523-1529
Number of pages7
JournalProstate
Volume79
Issue number13
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Prostatectomy
Prostatic Neoplasms
Pathology
Prostate-Specific Antigen
Neoplasms
Adenocarcinoma
Multivariate Analysis
Demography
Biopsy

Keywords

  • active surveillance
  • gleason upgrading
  • prostate cancer
  • radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance : How safe is it to depend on bioptic pathology? / Verep, Samed; Erdem, Selcuk; Ozluk, Yasemin; Kilicaslan, Isin; Sanli, Oner; Ozcan, Faruk.

In: Prostate, Vol. 79, No. 13, 01.01.2019, p. 1523-1529.

Research output: Contribution to journalArticle

@article{248e42eca1c249038d271e53cc1aef52,
title = "The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?",
abstract = "Background: Active surveillance (AS) is one of the treatment alternatives in low-risk prostate cancer (PCa). The pathological upgrading after radical prostatectomy (RP) were investigated in patients who were eligible for AS in the present study. Methods: Between August 2006 and July 2017, 627 patients underwent RP in our institution. One hundred and thirty-six patients who were eligible for AS at the time of RP were included in this study. The previously defined AS criteria Gleason 3 + 3=6 adenocarcinoma at maximum two biopsy cores, prostate-specific antigen (PSA) < 10 ng/mL and clinical T stage ≤ 2a were used in the study. The demographics, clinical, and histopathological outcomes were retrospectively compared between two groups, which were divided in accordance with the upgrading status at final pathology as Group 1 (n = 67, upgrading) and Group 2 (n = 69, nonupgrading). Results: Gleason upgrading (GU) was found in 67 (49.3{\%}) patients, and 17 patients (12.5{\%}) were upstaged to pT3a. The upgrading to Gleason 3 + 4 was reported in 38.7{\%} of patients, however, 7.4{\%}, and 3.7{\%} of the patients were upgraded to Gleason 4 + 3, and Gleason 4 + 4, respectively. The 10.3{\%} of the patients had extraprostatic involvement, and the rate (19.4{\%} vs 1.4{\%}, P =.002) was significantly higher in Group 1. PSA density (P =.001), tumor size (P <.001), tumor percentage (P <.001), apical involvement (P =.013), and perineural invasion (P <.001) in RP specimen were higher in Group 1. Multivariate analysis showed that perineural invasion (OR = 4.26; 95{\%}CI: 1.76-10.33; P =.001) and pathologic T stage (OR = 5.45; 95{\%}CI: 1.08-27.4; P =.04) were independently associated with GU. Conclusions: Since 12.5{\%} of the patients upstaged to pT3a disease, and there is a possible risk of Gleason 4 pattern, upgrading of the tumor should carefully be kept in mind before offering AS to low-risk patients with PCa.",
keywords = "active surveillance, gleason upgrading, prostate cancer, radical prostatectomy",
author = "Samed Verep and Selcuk Erdem and Yasemin Ozluk and Isin Kilicaslan and Oner Sanli and Faruk Ozcan",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pros.23873",
language = "English (US)",
volume = "79",
pages = "1523--1529",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "13",

}

TY - JOUR

T1 - The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance

T2 - How safe is it to depend on bioptic pathology?

AU - Verep, Samed

AU - Erdem, Selcuk

AU - Ozluk, Yasemin

AU - Kilicaslan, Isin

AU - Sanli, Oner

AU - Ozcan, Faruk

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Active surveillance (AS) is one of the treatment alternatives in low-risk prostate cancer (PCa). The pathological upgrading after radical prostatectomy (RP) were investigated in patients who were eligible for AS in the present study. Methods: Between August 2006 and July 2017, 627 patients underwent RP in our institution. One hundred and thirty-six patients who were eligible for AS at the time of RP were included in this study. The previously defined AS criteria Gleason 3 + 3=6 adenocarcinoma at maximum two biopsy cores, prostate-specific antigen (PSA) < 10 ng/mL and clinical T stage ≤ 2a were used in the study. The demographics, clinical, and histopathological outcomes were retrospectively compared between two groups, which were divided in accordance with the upgrading status at final pathology as Group 1 (n = 67, upgrading) and Group 2 (n = 69, nonupgrading). Results: Gleason upgrading (GU) was found in 67 (49.3%) patients, and 17 patients (12.5%) were upstaged to pT3a. The upgrading to Gleason 3 + 4 was reported in 38.7% of patients, however, 7.4%, and 3.7% of the patients were upgraded to Gleason 4 + 3, and Gleason 4 + 4, respectively. The 10.3% of the patients had extraprostatic involvement, and the rate (19.4% vs 1.4%, P =.002) was significantly higher in Group 1. PSA density (P =.001), tumor size (P <.001), tumor percentage (P <.001), apical involvement (P =.013), and perineural invasion (P <.001) in RP specimen were higher in Group 1. Multivariate analysis showed that perineural invasion (OR = 4.26; 95%CI: 1.76-10.33; P =.001) and pathologic T stage (OR = 5.45; 95%CI: 1.08-27.4; P =.04) were independently associated with GU. Conclusions: Since 12.5% of the patients upstaged to pT3a disease, and there is a possible risk of Gleason 4 pattern, upgrading of the tumor should carefully be kept in mind before offering AS to low-risk patients with PCa.

AB - Background: Active surveillance (AS) is one of the treatment alternatives in low-risk prostate cancer (PCa). The pathological upgrading after radical prostatectomy (RP) were investigated in patients who were eligible for AS in the present study. Methods: Between August 2006 and July 2017, 627 patients underwent RP in our institution. One hundred and thirty-six patients who were eligible for AS at the time of RP were included in this study. The previously defined AS criteria Gleason 3 + 3=6 adenocarcinoma at maximum two biopsy cores, prostate-specific antigen (PSA) < 10 ng/mL and clinical T stage ≤ 2a were used in the study. The demographics, clinical, and histopathological outcomes were retrospectively compared between two groups, which were divided in accordance with the upgrading status at final pathology as Group 1 (n = 67, upgrading) and Group 2 (n = 69, nonupgrading). Results: Gleason upgrading (GU) was found in 67 (49.3%) patients, and 17 patients (12.5%) were upstaged to pT3a. The upgrading to Gleason 3 + 4 was reported in 38.7% of patients, however, 7.4%, and 3.7% of the patients were upgraded to Gleason 4 + 3, and Gleason 4 + 4, respectively. The 10.3% of the patients had extraprostatic involvement, and the rate (19.4% vs 1.4%, P =.002) was significantly higher in Group 1. PSA density (P =.001), tumor size (P <.001), tumor percentage (P <.001), apical involvement (P =.013), and perineural invasion (P <.001) in RP specimen were higher in Group 1. Multivariate analysis showed that perineural invasion (OR = 4.26; 95%CI: 1.76-10.33; P =.001) and pathologic T stage (OR = 5.45; 95%CI: 1.08-27.4; P =.04) were independently associated with GU. Conclusions: Since 12.5% of the patients upstaged to pT3a disease, and there is a possible risk of Gleason 4 pattern, upgrading of the tumor should carefully be kept in mind before offering AS to low-risk patients with PCa.

KW - active surveillance

KW - gleason upgrading

KW - prostate cancer

KW - radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85070994318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070994318&partnerID=8YFLogxK

U2 - 10.1002/pros.23873

DO - 10.1002/pros.23873

M3 - Article

C2 - 31269285

AN - SCOPUS:85070994318

VL - 79

SP - 1523

EP - 1529

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 13

ER -